{
  "id": "bd0771426776c5e4",
  "title": "uniQure\u00a0N.V. (QURE): A Bear\u00a0Case Theory",
  "description": "We came across a bearish thesis on uniQure N.V. on augur\u2019s substack. In this article, we will summarize the bulls\u2019 thesis on QURE. uniQure N.V.\u2019s share was...",
  "content": "We came across a bearish\u00a0thesis on uniQure N.V. on augurs substack. In this article, we will summarize the bulls thesis on QURE. uniQure N.V.'s share was trading at $27.51 as of November 28th. QUREs \u2026 [+3716 chars]",
  "source": "Yahoo Entertainment",
  "source_url": "https://finance.yahoo.com/news/uniqure-n-v-qure-bear-171819405.html",
  "published_at": "2025-12-04T17:18:19Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "search:gene therapy CRISPR trial"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "Yahoo Entertainment"
    },
    "author": "Ricardo Pillai",
    "title": "uniQure\u00a0N.V. (QURE): A Bear\u00a0Case Theory",
    "description": "We came across a bearish thesis on uniQure N.V. on augur\u2019s substack. In this article, we will summarize the bulls\u2019 thesis on QURE. uniQure N.V.\u2019s share was...",
    "url": "https://finance.yahoo.com/news/uniqure-n-v-qure-bear-171819405.html",
    "urlToImage": "https://media.zenfs.com/en/insidermonkey.com/fc8de51b995d8c00fb14d0f74bed9539",
    "publishedAt": "2025-12-04T17:18:19Z",
    "content": "We came across a bearish\u00a0thesis on uniQure N.V. on augurs substack. In this article, we will summarize the bulls thesis on QURE. uniQure N.V.'s share was trading at $27.51 as of November 28th. QUREs \u2026 [+3716 chars]"
  }
}